Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.25    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Total Voting Rights

1 Apr 2021 07:00

RNS Number : 1755U
Genedrive PLC
01 April 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

 

 

Total Voting Rights

 

Genedrive plc (AIM: GDR) notifies the market that as at 31 March 2021 the Company's issued share capital comprises 63,320,048 ordinary shares with voting rights ('Shares'). No Shares are held in Treasury. As such, the number of Shares with voting rights is 63,320,048.

 

This figure may be used by shareholders (and others with notifiable obligations) as their denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Victoria Erskine

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDKDBKQBKDPNN
Date   Source Headline
1st Oct 202512:30 pmRNSHolding(s) in Company
30th Sep 20259:52 amRNSHolding(s) in Company
29th Sep 20255:03 pmRNSHolding(s) in Company
29th Sep 20253:00 pmRNSPublication of Circular and Notice of GM
29th Sep 20257:00 amRNSResult of Retail Offer
24th Sep 20257:00 amRNSCompletion of Placing
23rd Sep 20255:03 pmRNSProposed Retail Offer
23rd Sep 20254:59 pmRNSProposed Placing to raise a minimum of £3 million
23rd Sep 20259:00 amRNSHolding(s) in Company
23rd Sep 20259:00 amRNSHolding(s) in Company
15th Sep 20254:24 pmRNSResult of General Meeting
10th Sep 20254:15 pmRNSHolding(s) in Company
10th Sep 20254:15 pmRNSHolding(s) in Company
29th Aug 202512:00 pmRNSProposed Share Capital Reorganisation & GM
21st Aug 20257:00 amRNSScotland’s Public Health Minister visit
14th Aug 202510:35 amRNSComment re: Share Price Movement
11th Aug 20257:00 amRNSTrading update
30th May 20257:00 amRNSBlock Listing Returns
30th May 20257:00 amRNSCE-certification
13th May 20257:00 amRNSCYP2C19-ID Kit used to support expansion
2nd May 20251:30 pmRNSCYP2C19 ID Kit CE-IVD certification update
2nd Apr 20257:01 amRNSAdditional grant funding under DEVOTE programme
2nd Apr 20257:00 amRNSReceipt of R&D tax credit
1st Apr 20257:00 amRNSResult of RetailBook Offer
27th Mar 20253:30 pmRNSRetailBook Offer
27th Mar 20253:29 pmRNSHalf-year Report
27th Mar 20253:28 pmRNSEquity Fundraise
17th Mar 202511:04 amRNSScottish Government testing programme investment
14th Mar 20257:00 amRNSCYP2C19-ID Kit adopted for routine clinical use
30th Dec 202411:54 amRNSResult of AGM
27th Dec 20247:00 amRNSGenedrive® CYP2C19-ID Kit performance published
20th Dec 202412:16 pmRNSGrant of Options
20th Dec 202412:12 pmRNSDirector/PDMR Shareholding
5th Dec 20243:00 pmRNSPosting of annual report and notice of AGM
29th Nov 20241:00 pmRNSBlock listing returns
29th Nov 20247:00 amRNSFinal Results
22nd Nov 20247:00 amRNSNotice of Results
21st Nov 202411:06 amRNSNIHR and OLS Funding Package
4th Nov 20241:29 pmRNSScottish Health Technology Group publications
21st Oct 20243:22 pmRNSDirector Declaration
15th Aug 202410:39 amRNSDirector/PDMR Shareholding
12th Aug 20247:00 amRNSFirst UK commercial sales of the CYP2C19-ID Kit
6th Aug 20247:00 amRNSDirectorate Change
31st Jul 20247:00 amRNSNICE recommends CYP2C19-ID Kit in final guidance
15th Jul 20247:00 amRNSBreakthrough Device Designation from the U.S. FDA
27th Jun 20249:28 amRNSShort extension to NICE publication date
25th Jun 20247:00 amRNSHolding(s) in Company
24th Jun 202411:13 amRNSHolding(s) in Company
24th Jun 202411:12 amRNSHolding(s) in Company
24th Jun 202411:11 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.